Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations

A technology for memory loss and senile dementia, which is applied in the direction of drug combinations, pharmaceutical formulas, medical preparations containing active ingredients, etc., and can solve the problem of lack of very effective drugs

Active Publication Date: 2012-12-12
KPC PHARM INC
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The technical problem to be solved by the present invention is to provide the application of high mangiferin in the preparation of drugs for the prevention and treatment of senile dementia and memory loss in view of the lack of very effective drugs in the current treatment of senile dementia and memory loss

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations
  • Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations
  • Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1: Pharmacological experiment of high mangiferin

[0034] 1 Experimental materials, reagents and instruments

[0035] Experimental animals: 60 3-month-old APP695V717I transgenic mice (half male and half female), weighing 17-23 g, clean grade, and 15 C57BL / 6J mice with the same genetic background as normal controls. Animal license number SCXK Beijing 2005-0013.

[0036] Experimental drug: the positive control drug is selected donepezil hydrochloride (trade name: Aricept), 5 mg / tablet, pulverized during use, and dissolved in double distilled water.

[0037] Main instruments: DMS-2 Morris water maze instrument data automatic acquisition and processing system, STT-2 mouse platform jumper (or DT-200 platform automatic tester), BH-2 biological microscope, DpxView Pro computer color image processing system.

[0038] 2 Experimental methods

[0039] 2.1 Grouping and administration

[0040] APP transgenic mice were randomly divided into normal control group, model...

Embodiment 2

[0074] Embodiment 2: pharmaceutical composition

[0075]

Embodiment 3

[0076] Embodiment 3: pharmaceutical composition

[0077]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis. Researches shows that homomangiferin can improve damaged learning and memory ability of APP (amyloid protein precursor) transgenic mice evidently, and can improve relatively-long-term memory in short-term memory of the APP transgenic mice. The homomangiferin can increase content of Ach (acetylcholine), improve activity of CHAT (choline acetyl transferase) and inhibit activity of AchE (acetylcholinesterase), and accordingly indexes in terms of APP transgenic dementia model pathology, cholinergic system, cell apoptosis and the like can be improved. The homomangiferin and homomangiferin compositions can be used for preparing pharmaceuticals for preventing senile dementia and hypomnesis.

Description

technical field [0001] The invention relates to the field of drug application, in particular to the application of high mangiferin in the preparation of drugs for preventing and treating senile dementia and memory loss, as well as its pharmaceutical composition and preparation. Background technique [0002] The structure of homomangiferin is shown in formula I, which is a C-glycoside xanthone compound, and its full name is 1,6,7-trihydroxy-3-methoxy-2-C-β-D-glucopyranoside, Also known as 3-methoxymangiferin, the English name homomangiferin, also known as 1,6,7-trihydroxy-3-methoxy-2-C-β-D-glucopyranosyl-xanthone, exists in the Anacardiaceae plant mango (Mangifera indica L .), almond (Mangifera persiciformis C.) and other plants. [0003] [0004] Formula I [0005] Alzheimer's disease is a chronic disease caused by chronic progressive degeneration of the central nervous system. It is characterized by the slow development of neuropsychiatric symptoms such as memory impai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P25/28
Inventor 周荣光杨兆祥普俊学
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap